Fort L.P. trimmed its position in shares of Catalent Inc (NYSE:CTLT) by 37.8% during the 4th quarter, Holdings Channel reports. The firm owned 928 shares of the company’s stock after selling 564 shares during the period. Fort L.P.’s holdings in Catalent were worth $29,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in CTLT. Brown Advisory Inc. boosted its holdings in shares of Catalent by 11.0% during the 4th quarter. Brown Advisory Inc. now owns 2,890,711 shares of the company’s stock valued at $90,132,000 after acquiring an additional 285,768 shares during the last quarter. Gideon Capital Advisors Inc. purchased a new stake in shares of Catalent during the 4th quarter valued at about $397,000. Southeast Asset Advisors Inc. purchased a new stake in shares of Catalent during the 4th quarter valued at about $293,000. Flinton Capital Management LLC boosted its holdings in shares of Catalent by 2.7% during the 4th quarter. Flinton Capital Management LLC now owns 12,896 shares of the company’s stock valued at $402,000 after acquiring an additional 336 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Catalent by 4.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,326,230 shares of the company’s stock valued at $41,351,000 after acquiring an additional 55,260 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors.
In other Catalent news, SVP William Downie sold 7,315 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $42.00, for a total transaction of $307,230.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Lance Miyamoto sold 43,619 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
Shares of NYSE:CTLT opened at $42.20 on Monday. Catalent Inc has a twelve month low of $29.23 and a twelve month high of $46.43. The company has a current ratio of 2.08, a quick ratio of 1.63 and a debt-to-equity ratio of 1.36. The company has a market capitalization of $6.15 billion, a PE ratio of 26.54, a price-to-earnings-growth ratio of 2.29 and a beta of 1.70.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.08. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The firm had revenue of $623.00 million for the quarter, compared to analysts’ expectations of $608.38 million. During the same quarter in the prior year, the business earned $0.45 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. As a group, analysts expect that Catalent Inc will post 1.69 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://weekherald.com/2019/03/18/catalent-inc-ctlt-position-reduced-by-fort-l-p.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: What is a Lock-Up Period?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.